Dislipidemia in Patients with Rheumatoid Arthritis Treated with Synthetic DMARDS
Keywords:
rheumatoid arthritis, atherosclerosis, dyslipidemia, diagnostics, treatmentAbstract
Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by systemic inflammation, progressive joint destruction, and an increased risk of cardiovascular complications. Within a decade of diagnosis, one-third of RA patients develop cardiovascular issues, with subclinical atherosclerosis and myocardial ischemia being common manifestations. Changes in lipid profiles (LPs), marked by increased atherogenicity, play a crucial role in the pathogenesis of both RA and atherosclerosis. Seropositive RA, characterized by elevated anti-cyclic citrullinated peptide antibodies and rheumatoid factor, is associated with a higher risk of vascular complications. Early-stage RA presents diagnostic and therapeutic challenges, yet timely intervention using baseline therapies and adjunctive statin treatment has demonstrated efficacy in reducing RA activity and cardiovascular risk. Despite advancements, the detailed characterization of LP subfractions in RA remains underexplored, emphasizing the need for further research to elucidate the immunopathogenesis of atherosclerosis and optimize RA management strategies.
References
El-Barbary, A. M., Hussein, M. S., Rageh, E. M., Hamouda, H. E., Wagih, A. A., & Ismail, R. G. (2011). Effect of atorvastatin on inflammation and modification of vascular risk factors in rheumatoid arthritis. The Journal of Rheumatology, 38(2), 229–235.
Hörnberg, K., Pomeroy, J., Sandberg, C., Södergren, A., Ångström, L., Sundström, B., & Wållberg Jonsson, S. (2020). Physical activity in rheumatoid arthritis: Relationship to cardiovascular risk factors, subclinical atherosclerosis, and disease activity. Scandinavian Journal of Rheumatology, 49(2), 112–121. https://doi.org/10.1080/03009742.2019.1657491
Ibragimov, K. I. (2022). The risk of cardiovascular disease in rheumatoid arthritis patients treated with disease-modifying antirheumatic drugs: A clinic based case control study. Journal of Global Health Reports, 4(2). http://joghr.com/index.php/JGHR/article/view/32
Ibragimov, K., Sultonov, I., & Ravshanova, M. (2024). The Effectiveness of the Combination Therapy with biologic DMARDS in Rheumatoid Arthritis. Frontiers of Global Science, 2(1), 17–24.
Karpouzas, G. A., Ormseth, S. R., Hernandez, E., & Budoff, M. J. (2022). The impact of statins on coronary atherosclerosis progression and long-term cardiovascular disease risk in rheumatoid arthritis. Rheumatology, 61(5), 1857–1866.
Khasan, I., Ibrat, A., Islomovich, S. I., Sukhrobovna, R. M., Islamova, K., & Shuxrat, Z. (n.d.). The Association Between Cardiovascular Disease and Conventional DMARDs in Patients with Rheumatoid Arthritis. International Journal of Health Sciences, 6(S8), 5053–5059.
Lei, Q., Yang, J., Li, L., Zhao, N., Lu, C., Lu, A., & He, X. (2023). Lipid metabolism and rheumatoid arthritis. Frontiers in Immunology, 14, 1190607.
Popescu, D., Rezus, E., Badescu, M. C., Dima, N., Seritean Isac, P. N., Dragoi, I.-T., & Rezus, C. (2023). Cardiovascular risk assessment in rheumatoid arthritis: Accelerated atherosclerosis, new biomarkers, and the effects of biological therapy. Life, 13(2), 319.
Ravshanova, M., Ibragimov, K., Uralov, R., Xasanov, F., Islamova, K., Abdushukurova, K., Sultonov, I., & Axmedov, I. (2024). Clinical and Immunological Characteristics of Patients with Rheumatoid Arthritis on Synthetic DMARDS Therapy. Frontiers of Global Science, 2(1), 41–47.
Ristić, G. G., Subota, V., Lepić, T., Stanisavljević, D., Glišić, B., Ristić, A. D., Petronijević, M., & Stefanović, D. Z. (2015). Subclinical atherosclerosis in patients with rheumatoid arthritis and low cardiovascular risk: The role of von Willebrand factor activity. PLoS One, 10(8), e0130462.
Salmon, J. E., & Roman, M. J. (2008). Subclinical atherosclerosis in rheumatoid arthritis and systemic lupus erythematosus. The American Journal of Medicine, 121(10), S3–S8.
Sarmanova, A., Doherty, M., Kuo, C., Wei, J., Abhishek, A., Mallen, C., Zeng, C., Wang, Y., Lei, G., & Zhang, W. (2020). Statin use and risk of joint replacement due to osteoarthritis and rheumatoid arthritis: A propensity-score matched longitudinal cohort study. Rheumatology, 59(10), 2898–2907.
Tashinova, L., Khamraeva, N., Mambetova, L., Khasanov, F., & Ibragimov, K. (2023). Risk factors for the development of systemic lupus erythematosus (sle) in asians: A research case-control. BIO Web of Conferences, 65, 05017. https://www.bio-conferences.org/articles/bioconf/abs/2023/10/bioconf_ebwff2023_05017/bioconf_ebwff2023_05017.html
Toms, T. E., Panoulas, V. F., Douglas, K. M., Griffiths, H., Sattar, N., Smith, J. P., Symmons, D. P., Nightingale, P., Metsios, G. S., & Kitas, G. D. (2010). Statin use in rheumatoid arthritis in relation to actual cardiovascular risk: Evidence for substantial undertreatment of lipid-associated cardiovascular risk? Annals of the Rheumatic Diseases, 69(4), 683–688.
Yan, J., Yang, S., Han, L., Ba, X., Shen, P., Lin, W., Li, T., Zhang, R., Huang, Y., & Huang, Y. (2023). Dyslipidemia in rheumatoid arthritis: The possible mechanisms. Frontiers in Immunology, 14, 1254753.
